Psyence Biomedical Postpones Stock Split to February, Shares Decline

Psyence Biomedical Ltd. (PBM) caught investors off guard this week after announcing a last-minute postponement of its anticipated stock split. The biomedical company pushed back the effective date of its 1-for-6.25 reverse stock split from the originally scheduled January 20 to February 2, 2026. The market didn’t take the news well—PBM shares tumbled 5.05% in overnight trading, closing at $0.73 per share following the announcement.

Understanding the Consolidation Mechanics

The stock split, technically classified as a share consolidation, represents one of the most dramatic restructurings on the company’s books. Originally approved by the board on December 4, 2025, the plan consolidates every 6.25 existing shares into just one share post-split. As of January 21, the company had 6.39 million common shares in circulation. After this stock split takes effect, that number will compress dramatically to 1.02 million shares outstanding—a massive reduction that fundamentally alters the company’s capitalization structure.

Trading under the ticker symbol PBM on the Nasdaq Capital Market, the consolidated shares will operate under a new CUSIP identifier (74449F407), signaling the technical completion of the restructuring.

What’s Behind the Delay?

While Psyence hasn’t explicitly detailed the reasoning for the postponement, such delays typically reflect internal compliance considerations or final preparations to ensure a smooth transition. The two-week extension provided additional time for the company to finalize administrative details and notify stakeholders.

Impact for Shareholders

The postponement means current shareholders holding PBM stock will see their share counts reduced significantly once February 2 arrives. What previously meant owning 6.25 shares now translates to owning a single consolidated share—a shift that affects everything from voting power calculations to portfolio rebalancing strategies. For active traders monitoring PBM, the transition marks a critical inflection point where historical price comparisons must account for the new post-split basis.